Kalaris Therapeutics (NASDAQ:KLRS) & Travere Therapeutics (NASDAQ:TVTX) Head-To-Head Contrast

Kalaris Therapeutics (NASDAQ:KLRS) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for Kalaris Therapeutics and Travere Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1	0	6	1	2.88
Travere Therapeutics	1	2	10	0	2.69

Kalaris Therapeutics presently has a consensus target price of $18.75, suggesting a potential upside of 349.64%. Travere Therapeutics has a consensus target price of $61.67, suggesting a potential downside of 6.51%. Given Kalaris Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Kalaris Therapeutics is more favorable than Travere Therapeutics.

Profitability

This table compares Kalaris Therapeutics and Travere Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

Valuation & Earnings

This table compares Kalaris Therapeutics and Travere Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44 million	($2.02)	-2.06
Travere Therapeutics	$490.73 million	12.67	-$25.55 million	($0.46)	-143.39

Travere Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

66.0% of Kalaris Therapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Kalaris Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.

About Kalaris Therapeutics

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

About Travere Therapeutics

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.